Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Novo Nordisk (NVO) faces a 6% premarket drop after clinical trial results for its obesity drug CagriSema fell below ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...

H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema a ...

The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

A new study claims there are two kinds of obesity – one of which puts you at risk of major health problems. Find out which ...